Anzeige
Mehr »
Login
Sonntag, 14.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Spezial: Montag letzte Chance vor großer Verkündung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PY7P | ISIN: US07373V1052 | Ticker-Symbol:
NASDAQ
12.04.24
22:00 Uhr
25,930 US-Dollar
-1,300
-4,77 %
1-Jahres-Chart
BEAM THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
BEAM THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur BEAM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.03.Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK222WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)...
► Artikel lesen
26.03.Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)88CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the...
► Artikel lesen
06.03.Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments10
28.02.Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences9
27.02.Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat10
27.02.JPMorgan raises Beam Therapeutics stock target to $44 from $4015
27.02.Recap: Beam Therapeutics Q4 Earnings13
27.02.Beam Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans4
27.02.Beam Therapeutics Inc reports results for the quarter ended in December - Earnings Summary12
27.02.Beam Therapeutics Inc. - 10-K, Annual Report2
27.02.Beam Therapeutics Inc. - 8-K, Current Report4
27.02.Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones342Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation...
► Artikel lesen
16.02.Beam Therapeutics Stock Shows Healthy Relative Strength Improvement6
05.02.Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference8
30.01.Why Beam Therapeutics Stock Zoomed 17% Higher Today26
29.01.US Beam Therapeutics, Lam Research, Vir Biotechnology26
08.01.Beam Therapeutics Inc. - 8-K, Current Report3
08.01.Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones235First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data...
► Artikel lesen
02.01.Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference3
14.12.23Beam Therapeutics Inc. - 8-K, Current Report3
Seite:  Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,1